Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity—Report of a Case and Review of the Literature

Secondary autoimmunity is the most frequent adverse event occurring in almost every other alemtuzumab-treated multiple sclerosis patient. We report a case of a patient with relapsing-remitting multiple sclerosis who reported smooth, circular areas of complete hair loss on both thighs 6 months after...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Julian, Buhl, Timo, Müller, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670499/
https://www.ncbi.nlm.nih.gov/pubmed/29163335
http://dx.doi.org/10.3389/fneur.2017.00569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670499/
https://www.ncbi.nlm.nih.gov/pubmed/29163335
http://dx.doi.org/10.3389/fneur.2017.00569

Ejemplares similares